Czernin et al. [52] showed in a preclinical xenograft mouse model for CRPC that combining [225Ac]Ac-PSMA-617 and an anti-programmed death 1 (PD-1) antibody provides an advantage for tumor growth control and survival. Here, FOLH1 is linked to neoplasm.